Kelactin 50 microgram Oral Solution for Dogs & Cats 7ml

Kelactin 50 Microgram Oral Solution for Dogs & Cats 7ml

Kelactin is an oral dog and cat medication used to treat false pregnancy in bitches and suppression of lactation in bitches and queens. It contains the active substance cabergoline which is a pale yellow, viscous oily solution that inhibits processes such as lactation.

Kelactin works by binding to dopamine receptors in the pituitary gland, which prevents the release of prolactin. This reduces milk production and helps to dry up milk secretion. It also suppresses false pregnancy symptoms such as nesting behaviour and mammary gland development in bitches.

How To Buy Kelactin For Cats & Dogs

Kelactin for dogs and cats is a non-prescription medication that can be bought from our online store. This product must be kept refrigerated and so express delivery is required. Buying your cat and dog medication online is a simple process that means you can buy kelactin online instead of going to your vet every month.

How To Use Kelactin For Cats & Dogs

The veterinary medicinal product should be administered orally either directly into the mouth or by mixing with food. The dosage is 0.1 ml/kg bodyweight (equivalent to 5 microgram/kg bodyweight of cabergoline) once daily for 4-6 consecutive days, depending on the severity of the clinical condition. The weight of the treated animal should be accurately determined before administration.

Target species

Dog and cat.

4.2 Indications for use, specifying the target species

The veterinary medicinal product is indicated for the following uses:

• Treatment of false pregnancy in bitches
• Suppression of lactation in bitches and queens

4.3 Contra-indications

Do not use in pregnant animals since the product may cause abortion. Do not use with dopamine antagonist. Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Cabergoline may induce transient hypotension in treated animals. Do not use in animals concurrently being treated with hypotensive drugs. Do not use directly after surgery whilst the animal is still under the influence of the anaesthetic agents.

4.4 Special warnings for each target species

Additional supportive treatments should involve restriction of water and carbohydrate intake and increase exercise.

4.5 Special precautions for use

i) Special precautions for use in animals

Not applicable.

(ii) Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash hand after use. Avoid contact with skin and eyes. Wash of any splashes immediately. Women of childbearing potential and breast-feeding woman should not handle the product or should wear disposable gloves when administering the product. People with known hypersensitivity to cabergoline or any of the other ingredients in the product should avoid contact with the veterinary medicinal product. Do not leave unattended filled syringes in presence of children. In the event of accidental ingestion, particularly by a child, seek medical attention immediately and show the package leaflet or the label to the physician.

4.6 Adverse reactions (frequency and seriousness)

Possible adverse effects are:

• sleepiness
• anorexia
• vomiting

These adverse effects are usually of a moderate and transient nature. Vomiting usually only occurs after the first administration. In this case treatment should not be stopped, since the vomiting will not reoccur after the following administrations. In very rare cases allergic reactions may occur, such as oedema, urticaria, dermatitis and pruritus. In very rare cases a transient hypotension may occur. In very rare cases neurological symptoms may occur, such as sleepiness, muscle tremor, ataxia, hyperactivity and convulsions.

The frequency of adverse reactions is defined using the following convention:

• very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
• common (more than 1 but less than 10 animals in 100 animals)
• uncommon (more than 1 but less than 10 animals in 1,000 animals)
• rare (more than 1 but less than 10 animals in 10,000 animals)
• very rare (less than 1 animal in 10,000 animals, including isolated reports).

4.7 Use during pregnancy, lactation or lay

Cabergoline has the capacity to cause abortion in the later stages of pregnancy and should not be used in pregnant animals. Differential diagnosis between pregnancy and false pregnancy should be made correctly. The product is indicated for the suppression of lactation: inhibition of prolactin secretion by cabergoline results in a rapid cessation of lactation and a reduction in the size of the mammary glands. The product should not be used in lactating animals unless suppression of lactation is required.

4.8 Interaction with other medicinal products and other forms of interaction

Since cabergoline exerts its therapeutic effect by direct stimulation of dopamine receptors, the product should not be administered concurrently with drugs which have dopamine antagonist activity (such as phenothiazines, butyrophenones, metoclopramide), as these might reduce its prolactin inhibiting effects.

Since cabergoline may induce transient hypotension, the product should not be used in animals concurrently treated with hypotensive drugs.

Vat Rate: 20%